Amgen v Sanofi: Big Pharma awaits SCOTUS decision

The Supreme Court recently granted a petition for a writ of certiorari in a case concerning an issue of significant importance in the pharmaceutical and chemical technology industry.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Don’t distort enablement law, Amgen tells SCOTUS

9 March 2023 Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.

Big Pharma

Sanofi backed by big pharma and more in SCOTUS clash

Big Pharma

Amgen asks Fed Circ to rehear $1.1bn Juno patent suit

16 November 2021 Amgen and two research centres have thrown their support behind Bristol Myers Squibb subsidiary Juno Therapeutics to help restore a $1.1 billion patent judgment against Kite Pharma that was overturned by the US Court of Appeals for the Federal Circuit.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Barnes & Thornburg reveals five new IP leaders

Amgen v Sanofi: Big Pharma awaits SCOTUS decision

More on this story

Editor's picks

Editor's picks

More features